Apimeds Pharmaceuticals US, Inc.

Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.

APUS | US

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: 100 MATAWAN RD, 7747 MATAWAN
Website:: https://www.apimedsus.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Apimeds Pharmaceuticals US, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies to treat inflammation and pain. The company's lead program is Apitox, a novel, non-narcotic therapy derived from purified honey bee venom. Apitox is being clinically studied for treating pain and inflammation, particularly in patients with osteoarthritis. Apimeds operates on a principle it calls 'Actual Intelligence (ai²™),' which emphasizes human experience, scientific rigor, and clinical judgment to identify and develop overlooked or distressed clinical assets. This approach guides the company in navigating regulatory, intellectual property, and market access challenges, with a primary commitment to patients and physicians.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Apimeds Pharmaceuticals US, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Apimeds Pharmaceuticals US, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Apimeds Pharmaceuticals US, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Emergent BioSolutions Inc. Develops and manufactures medical countermeasures for public health and national security threats.	United States of America	EBS
ENANTA PHARMACEUTICALS INC Developing novel small molecule drugs for virology (HCV, RSV) and immunological diseases.	United States of America	ENTA
enGene Holdings Inc. Developing non-viral, locally administered gene therapies for rare genetic conditions.	United States of America	ENGN
Enliven Therapeutics, Inc. A clinical-stage biopharma developing kinase inhibitors for precision oncology cancer treatment.	United States of America	ELVN
Enlivex Therapeutics Ltd. Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.	Israel	ENLV
Enlivex Therapeutics Ltd. Developing cell therapy that reprograms macrophages to treat immune hyper-responses like sepsis.	United States of America	ENLV
Enorama Pharma AB Develops & makes consumer nicotine products & medicated gums, offering private label solutions.	Sweden	ERMA
Ensysce Biosciences, Inc. Developing safer opioids with abuse-deterrent and overdose protection technology for severe pain.	United States of America	ENSC
Entera Bio Ltd. Developing oral versions of injectable drugs for osteoporosis, hypoparathyroidism, and obesity.	United States of America	ENTX
Entero Therapeutics, Inc. Develops targeted oral therapies for a range of gastrointestinal (GI) diseases.	United States of America	ENTO